Imaging study of new cancer-targeting radioactive drugs
Part of Cancer, Kidney & urinary, Skin clinical trials.
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic (spread) breast cancer or prostate cancer confirmed by biopsy
- Your cancer has progressed despite standard treatments
- You have at least one tumor visible on imaging that is at least 1 cm in size
- Your blood counts and organ function (liver, kidney) are adequate
- You can hold still for up to 60 minutes during imaging scans
- You are willing to use effective birth control for 6 months after the study drug (if of childbearing potential)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
This study tests a new approach that first uses a special scan to find cancer cells that have a specific marker, then delivers targeted radiation to those cells. It is designed for people with advanced solid tumors that have spread and stopped responding to standard treatments.
This research study tests a new imaging scan (called 68Ga-OncoACP3-PET/CT) to help find prostate cancer and see where it may have spread. The scan uses a radioactive tracer to help doctors visualize cancer cells and decide on the best treatment options.
This trial tests a new type of PET scan using a radioactive tracer called [68Ga]DOTA-IR-780-C-4 to see if it can find prostate cancer cells that express a protein called PSMA. If you have advanced prostate cancer that has stopped responding to standard treatments, this scan may help your doctor better understand your cancer and possibly guide future care.
This trial tests a new targeted radioactive drug that seeks out a specific marker on lung cancer cells. It first uses a low-dose imaging scan to see if the cancer cells have this marker, then gives a higher-dose treatment to destroy those cells.
This early-phase study tests a cancer medicine that uses radiation to target prostate cancer cells that carry a specific marker (PSMA). It may help people whose metastatic prostate cancer has stopped responding to hormone therapy and/or chemotherapy.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.